Increasing prevalence of metastatic castration-resistant prostate cancer in a managed care population in the United States-Reference-Cited by-同舟云学术

Increasing prevalence of metastatic castration-resistant prostate cancer in a managed care population in the United States

Published:2021-08-12 Issue:12 Volume:32 Page:1365-1374
ISSN:0957-5243
Container-title:Cancer Causes & Control
language:en
Short-container-title:Cancer Causes Control

Author:

Wallace Katrine L.^ORCID,Landsteiner Adrienne,Bunner Scott H.,Engel-Nitz Nicole M.,Luckenbaugh Amy N.

Funder

Clovis Oncology

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s10552-021-01484-4.pdf

Reference23 articles.

1. Siegel RL, Miller KD, Jemal A (2020) Cancer statistics. CA Cancer J Clin 70(1):7–30. https://doi.org/10.3322/caac.21590

2. Ritch C, Cookson M 2018 Recent trends in the management of advanced prostate cancer. F1000Res 7(F1000 Faculty Rev) Doi: https://doi.org/10.12688/f1000research.15382.1

3. Scher HI, Solo K, Valant J, Todd MB, Mehra M (2015) Prevalence of prostate cancer clinical states and mortality in the United States: estimates using a dynamic progression model. PLoS ONE 10(10):e0139440. https://doi.org/10.1371/journal.pone.0139440

4. Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, Antonarakis ES, Beer TM, Carducci MA, Chi KN, Corn PG, de Bono JS, Dreicer R, George DJ, Heath EI, Hussain M, Kelly WK, Liu G, Logothetis C, Nanus D, Stein MN, Rathkopf DE, Slovin SF, Ryan CJ, Sartor O, Small EJ, Smith MR, Sternberg CN, Taplin ME, Wilding G, Nelson PS, Schwartz LH, Halabi S, Kantoff PW, Armstrong AJ (2016) Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol 34(12):1402–1418. https://doi.org/10.1200/jco.2015.64.2702

5. Agency for Healthcare Research and Quality (2017) Clinical Classifications Software (CCS) for ICD-9-CM. www.hcup-us.ahrq.gov/toolssoftware/ccs/ccs.jsp. Accessed 16 February 2021

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pain and Health-related Quality of Life with Biweekly Versus Triweekly Cabazitaxel Schedule in Older Men with Metastatic Castration-resistant Prostate Cancer in the Multicenter, Randomized CABASTY Trial;European Urology Oncology;2024-08

2. Demonstrating Bioequivalence for Two Dose Strengths of Niraparib and Abiraterone Acetate Dual-Action Tablets Versus Single Agents: Utility of Clinical Study Data Supplemented with Modeling and Simulation;Clinical Pharmacokinetics;2024-03-04

3. Prostate Cancer Liver Metastasis: An Ominous Metastatic Site in Need of Distinct Management Strategies;Journal of Clinical Medicine;2024-01-27

4. Oncological Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide with versus Without Confirmatory Bone Scan;Cancer Research and Treatment;2023-12-05

5. Breaking through resistance in mCRPC: Enzalutamide analogues as effective anticancer agents for enhanced male survival;Results in Chemistry;2023-12